Share your videos with the world

Sign Up | Log In | Help  

   
 
Related Tags: health  medical  device  3d  fda  gore  procedure  stroke  heart  multivu  8301551  health  hospital  medicine  healthcare  treatments  new  technology  northwestern  medicine  multivu  8213351  disease  health  research  healthcare  treatment  technology  new  help  wellness  multivu  8268751  pancreatic  cancer  health  disease  symposium  awareness  treatments  survivors  multivu  8213752  researchers  dietary  banned  stimulants  unapproved  pills  recall  medical  multivu  8216951  healthcare  health  data  technology  physicians  clinical  medicomp  it  multivu  8189651  woman  health  comfort  replens  gel  dryness  vaginal  menopause  multivu  8066251  delta  technology  health  medtech  medical  fda  lithotripter  new  healthcare  multivu  8134451  webmd  health  healthcare  medical  treatment  migraine  headache  robin  roberts  multivu  7579759  fda  brain  cancer  health  healthcare  treatment  medicine  glioma  multivu  7944251  varian  medical  systems  halcyon  health  healthcare  cancer  treatment  imrt  multivu  8065951  health  bvi  body  volume  indicator  bmi  research  weight  mayo  clinic  multivu  8093051 
Search // clinical
Results 1-12 of 98 for ' clinical ' (5 seconds)
Following the unprecedented Gore REDUCE Clinical Study conclusion that closure of patent foramen ovale (PFO) can prevent recurrent ischemic strokes, W. L. Gore & Associates, Inc. (Gore) has received approval from the U.S. Food and Drug Administration (FDA) for an expanded indication for its GORE® CARDIOFORM Septal Occluder. The device, already approved for closure of atrial septal defects (ASDs) up to 17 mm, is now also approved for the closure of PFO to reduce the risk of recurrent ischemic stroke in certain patients.* To view the multimedia release go to: https://www.multivu.com/players/English/8301551-gore-cardioform-septal-occluder-fda-approval/
Categories // Miscellaneous 
Added: 135 days ago by MultiVuVideos
Runtime: 1m8s | Views: 4 | Comments: 4
Not yet rated
 

 

 

After nearly eight years of careful planning, guests from across Illinois gathered today in Lake Forest to celebrate the ceremonial opening of the new Northwestern Medicine Lake Forest Hospital, which will officially open on March 3, 2018. The new state-of-the-art hospital, which broke ground in 2014, will provide patients convenient access to world-class physicians with seamless access to Northwestern Memorial Hospital, Illinois’s premier academic medical center when needed. The new Lake Forest Hospital will offer cutting-edge treatments and innovative clinical trials within a world class health system. To view the multimedia release go to: https://www.multivu.com/players/English/8213351-new-northwestern-medicine-lake-forest-hospital/
Categories // Miscellaneous 
Added: 184 days ago by MultiVuVideos
Runtime: 1m6s | Views: 4 | Comments: 2
Not yet rated
 

 

 

TransCelerate BioPharma Inc., a non-profit organization dedicated to improving the health of people around the world by simplifying and accelerating research and development of innovative new therapies, has unveiled a new global campaign designed to help increase awareness of the growing need for clinical trial participants. The campaign, called “One Person Closer,” focuses on inspiring healthcare professionals (HCPs) to consider clinical research as a possibility for their patients, incorporate the topic into their daily practices, and have meaningful conversations with patients about opportunities to participate in clinical trials. One Person Closer is designed to put a human face on research and development by sharing the personal stories of researchers, HCPs and patients who have contributed to clinical research and the development of medical breakthroughs. The photojournalist campaign aims to show doctors, nurses and other HCPs that they can help facilitate research that advances science and that may benefit their patients. To view the multimedia release go to: https://www.multivu.com/players/English/8268751-transcelerate-biopharma-one-person-closer/
Categories // Miscellaneous 
Added: 190 days ago by MultiVuVideos
Runtime: 1m28s | Views: 5 | Comments: 3
Not yet rated
 

 

 

Let’s Win, an initiative supported by the Lustgarten Foundation, launched the Let’s Win! Pancreatic Cancer Survivors video series Friday, January 19, 2018, at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. The new online video series, featuring long-term pancreatic cancer survivors of all ages and diverse backgrounds, has been created to show pancreatic cancer patients and their families that people do survive this disease. The survivors have responded exceptionally well to pancreatic cancer therapy that incorporates clinical trials and treatments that go beyond traditional protocols. When patients are first diagnosed with pancreatic cancer, they often turn to the internet, only to find devastating and frightening statistics about the disease. “Our goal is to provide hope and inspiration to patients and their families,” says Cindy Gavin, founding executive director of Let’s Win. “We are so grateful for the incredible vision of one special patient and the generosity of The Flora Family Foundation for their support of this incredible initiative.” To view the multimedia release go to: https://www.multivu.com/players/English/8213752-lets-win-pancreatic-cancer-survivor-video-series/
Categories // Miscellaneous 
Added: 205 days ago by MultiVuVideos
Runtime: 3m51s | Views: 5 | Comments: 2
Not yet rated
 

 

 

Researchers at global public health organization NSF International, Harvard Medical School, the United States Department of Defense and the National Institute for Public Health and the Environment in the Netherlands (RIVM) recently identified four unapproved, DMAA-like stimulants in six over-the-counter weight-loss and pre-workout products currently available online. The research was published in the peer-reviewed journal Clinical Toxicology. The potentially harmful compounds – including banned stimulants 1,3-DMAA and 1,3-DMBA as well as octodrine and a newly identified DMAA analog – were not listed as ingredients in the products and may have been disguised as “2-aminoisoheptane” or extract of Aconitum kusnezoffii. These stimulants may cause adverse cardiac events, hemorrhagic strokes or sudden death, especially if taken prior to strenuous exercise or combined with caffeine. Extreme heat and dehydration may also increase the health risks. To view the multimedia release go to: https://www.multivu.com/players/English/8216951-nsf-international-banned-stimulants-2-aminoisoheptane/
Categories // Miscellaneous 
Added: 280 days ago by MultiVuVideos
Runtime: 1m33s | Views: 7 | Comments: 1
Not yet rated
 

 

 

According to recent survey by Medicomp Systems, 43 percent of healthcare IT professionals and physicians cited that their top data-related challenge was not a lack of data but rather the struggle to access the right data at the right time. Those findings aren't surprising since the vast majority of health information systems today share a common design flaw: they don't think and work the way physicians do at the point of care. However, they are still deeply concerning. To deliver the best patient care, physicians need clinically relevant data that is seamlessly presented within their current workflows and integrated into the same workspace. The result is not only better patient care and better outcomes but also higher clinical effectiveness, efficiency, and satisfaction. To view the multimedia release go to: https://www.multivu.com/players/English/8189651-medicomp-systems-ebook-healthcare-data-challenges/
Categories // Miscellaneous 
Added: 281 days ago by MultiVuVideos
Runtime: 1m44s | Views: 5 | Comments: 1
Not yet rated
 

 

 

The complete solution to managing vaginal dryness and discomfort inside and out is now available to the millions of women changing physically, emotionally and hormonally every day. The maker of #1 doctor recommended Replens™ vaginal moisturizer introduces hormone-free and fragrance-free Replens™ Moisture Restore External Comfort Gel, for soothing relief from external vaginal dryness, in menopause, post-partum, and after a cancer diagnosis. “Ladies, don’t despair. Vaginal dryness can be a nuisance at any age. It’s one of the most common symptoms of menopause and unfortunately, can worsen over time. Luckily, there are non-hormonal products like Replens,” says Mary Jane Minkin, M.D., Clinical Professor of Obstetrics, Gynecology and Reproductive Sciences at Yale University. “I recommend these products to patients as first line therapies to help relieve internal and external vaginal dryness.” To view the multimedia release go to: https://www.multivu.com/players/English/8066251-replens-vaginal-moisture-restore-external-comfort-gel/
Categories // Miscellaneous 
Added: 366 days ago by MultiVuVideos
Runtime: 0m52s | Views: 2 | Comments: 1
Not yet rated
 

 

 

Today, WebMD released In Their Own Words: Moving Beyond Migraine with Robin Roberts, a new five-part video series that sheds light on the debilitating nature of migraine and the impact it has on all aspects of a sufferer’s personal and professional life. To learn more about treatments and the individuals featured in In Their Own Words: Moving Beyond Migraine with Robin Roberts, visit: to www.webmd.com/insidemigraines. Moving Beyond Migraine follows the lives of Jennifer, a public school administrator who has lived with intense migraine headaches for over 20 years; Kate, a 20-year-old college student with debilitating migraines that have run in her family for generations; Melanie, whose intense migraine condition has altered the dynamics of her nine year marriage; and Lynn, who after suffering from migraine for 50 years, shares how a clinical trial for a new treatment called CGRP targeted therapy is finally providing her with some relief. To view the multimedia release go to: https://www.multivu.com/players/English/7579759-robin-roberts-moving-beyond-migraine/
Categories // Miscellaneous 
Added: 416 days ago by MultiVuVideos
Runtime: 1m4s | Views: 7 | Comments: 1
Not yet rated
 

 

 

A first-of-a-kind neural stem cell therapy that works with a common cold virus to seek out and attack a lethal and aggressive brain cancer is being tested at Northwestern Medicine in a Phase I clinical trial for patients newly diagnosed with malignant glioma. The novel drug to treat malignant glioma, notorious for recurring after typical bouts of standard cancer treatment, was developed by a Northwestern scientist and has been approved as an investigational drug by the U.S. Food and Drug Administration. This is only the second time the University has supported and filed an investigational new drug as a sponsor. To view the multimedia release go to: https://www.multivu.com/players/English/7944251-northwestern-medicine-stem-cell-trial/
Categories // Miscellaneous 
Added: 420 days ago by MultiVuVideos
Runtime: 4m28s | Views: 8 | Comments: 1
Not yet rated
 

 

 

Varian Medical Systems (NYSE: VAR) today is introducing the Halcyon™ system, an entirely new device for cancer treatment. Engineered to revolutionize clinical workflow, Halcyon simplifies and enhances virtually every aspect of image-guided volumetric intensity modulated radiotherapy (IMRT). This new treatment system is designed to expand the availability of high quality cancer care globally and help save the lives of millions more cancer patients. “The global cancer challenge is enormous,” said Kolleen Kennedy, president of Varian's Oncology Systems business. “It is expected that there will be 24.6 million cancer cases diagnosed annually by 2030, and there is an acute shortage of equipment and trained clinicians. With the innovations in this new technology platform, the system will deliver high quality Halcyon treatments that empower clinicians to care for many more patients. At Varian we are very excited with the introduction of Halcyon to be taking another big step toward advancing cost-effective cancer care worldwide.” To view the multimedia release go to: https://www.multivu.com/players/English/8065951-varian-medical-systems-halcyon-cancer-treatment/
Categories // Miscellaneous 
Added: 465 days ago by MultiVuVideos
Runtime: 3m34s | Views: 6 | Comments: 0
Not yet rated
 

 

 

Today, the newly-developed Body Volume Indicator (BVI)™ was revealed as a modern day measure of body composition and weight distribution following a 10-year collaboration with Mayo Clinic experts who led extensive research on fat distribution, the importance of fat assessment and the limitations of the current standard of Body Mass Index (BMI). In conjunction with the development of BVI, BVI America LLC, a subsidiary of 3D measurement pioneer Select Research, announced the launch of the revolutionary BVI Pro tablet application, which will provide an easily accessible and affordable means for the professional community to use the new BVI measurement in everyday clinical use to assess health risks. The potential benefits of using Body Volume as a new indicator of risks were presented on April 27 by Mayo Clinic researchers, BVI America and the University of Westminster. It draws on 10 years of rigorous research, testing and validation using several potential Body Volume indices. Now BVI, calculated as a ratio between total volume and abdominal volume, can be used as a supplement to the current measurement standard of BMI, which is based solely on height and weight. BVI is considered to be a more precise means of estimating weight distribution and the fat around the organs, which is not visible to the human eye and can lead to serious health conditions, such as diabetes and heart disease. The medical and professional community at large is invited to contribute to the continued development of BVI by downloading and using the BVI Pro tablet application with their patients and clients; anonymous data collected will be analyzed by Mayo Clinic, whose research and validation of BVI will continue. To view the multimedia release go to: https://www.multivu.com/players/English/8093051-bvi-america-body-volume-app-health-fitness/
Categories // Miscellaneous 
Added: 472 days ago by MultiVuVideos
Runtime: 1m57s | Views: 6 | Comments: 0
Not yet rated
 

 

 

Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, commemorated its 50-year anniversary by awarding $150,000 in total grants to three organizations that share its goal to improve healthcare: The American Red Cross, the National Ovarian Cancer Coalition and Autism Speaks. At a ceremony at the company’s flagship clinical laboratory in Teterboro, NJ, the company’s chairman, president and CEO Steve Rusckowski presented Health In Your Hands grants of $50,000 to representatives from each organization. Paul Brown, M.D., founder and former CEO of Quest’s predecessor company Metropolitan Pathology Laboratory, Inc. or MetPath, established in April, 1967, was also recognized at the event. To view the multimedia release go to: https://www.multivu.com/players/English/8080751-quest-diagnostics-50th-anniversary/
Categories // Miscellaneous 
Added: 479 days ago by MultiVuVideos
Runtime: 4m1s | Views: 6 | Comments: 0
Not yet rated
 

 

 

Page 1 of 9  |  Go to page    Next» LAST»»



About Us   |   Help  |   Advertise on ClipMoon   |   Terms of Use   |   Privacy Policy   |   Copyright   |   Contact   |   Link us   |   RSS 
Copyright © 2007-2018 ClipMoon.com. All rights reserved.